Search hospitals > Illinois > Glenview

NorthShore University HealthSystem-Glenbrook Hospital

Claim this profile
Glenview, Illinois 60026
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Recurrence
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast Cancer
133 reported clinical trials
15 medical researchers
Photo of NorthShore University HealthSystem-Glenbrook Hospital in GlenviewPhoto of NorthShore University HealthSystem-Glenbrook Hospital in GlenviewPhoto of NorthShore University HealthSystem-Glenbrook Hospital in Glenview

Summary

NorthShore University HealthSystem-Glenbrook Hospital is a medical facility located in Glenview, Illinois. This center is recognized for care of Cancer, Lung Cancer, Recurrence, Non-Small Cell Lung Cancer, Breast Cancer and other specialties. NorthShore University HealthSystem-Glenbrook Hospital is involved with conducting 133 clinical trials across 255 conditions. There are 15 research doctors associated with this hospital, such as Mary T Jenkins Vogel, MD, Bruce E. Brockstein, Poornima Saha, and Robert d. Marsh.

Area of expertise

1Cancer
Global Leader
NorthShore University HealthSystem-Glenbrook Hospital has run 51 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage I
2Lung Cancer
Global Leader
NorthShore University HealthSystem-Glenbrook Hospital has run 26 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage II
Stage I

Top PIs

Clinical Trials running at NorthShore University HealthSystem-Glenbrook Hospital

Breast Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Lung Cancer
Diffuse Large B-Cell Lymphoma
Cancer
Squamous Cell Carcinoma
Lymphoma
Bladder Cancer
Ovarian Tumors
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Omitting Radiation Therapy

for Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at NorthShore University HealthSystem-Glenbrook Hospital?
NorthShore University HealthSystem-Glenbrook Hospital is a medical facility located in Glenview, Illinois. This center is recognized for care of Cancer, Lung Cancer, Recurrence, Non-Small Cell Lung Cancer, Breast Cancer and other specialties. NorthShore University HealthSystem-Glenbrook Hospital is involved with conducting 133 clinical trials across 255 conditions. There are 15 research doctors associated with this hospital, such as Mary T Jenkins Vogel, MD, Bruce E. Brockstein, Poornima Saha, and Robert d. Marsh.